000028 国药一致
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)3.2356.2623.6639.5369.576
总资产报酬率 ROA (%)1.2462.3511.3513.5473.482
投入资产回报率 ROIC (%)1.8483.4311.9935.3315.305

边际利润分析
销售毛利率 (%)10.04310.68011.09111.99312.154
营业利润率 (%)2.3012.0610.7713.2693.140
息税前利润/营业总收入 (%)2.4752.3051.0963.5483.405
净利润/营业总收入 (%)1.7861.5370.3192.5952.412

收益指标分析
经营活动净收益/利润总额(%)92.830106.230236.50688.96892.314
价值变动净收益/利润总额(%)10.85314.62838.4248.9717.269
营业外收支净额/利润总额(%)-0.852-0.2520.3460.2350.216

偿债能力分析
流动比率 (X)1.5791.5401.5151.4941.508
速动比率 (X)1.2531.2291.2161.1661.135
资产负债率 (%)54.54855.95556.35655.90254.372
带息债务/全部投入资本 (%)36.70740.85339.35838.61734.713
股东权益/带息债务 (%)161.536134.875138.425140.732166.172
股东权益/负债合计 (%)71.82767.74265.93065.48669.595
利息保障倍数 (X)12.7779.2483.40413.09213.195

营运能力分析
应收账款周转天数 (天)109.959100.31590.84276.13672.863
存货周转天数 (天)44.91242.62241.90542.88343.126